Claudin18.2 是肿瘤靶向免疫治疗的新型分子生物标志物
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
62.5分
★★★☆☆
DISEASE HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
CLDN18.2 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells.
我们的研究结果表明,靶向CLDN18.2的CAR-T细胞有望成为治疗表达CLDN18.2的LUAD的一种有效治疗策略。
MEMBER ACCOUNT
登录成功会直接打开下一页。